HB917 revises Virginia’s pharmacy compounding laws, focusing on when pharmacists may compound drugs, what ingredients they may use, how compounded products must be labeled, and what records must be kept. The bill amends provisions governing the Board of Pharmacy’s confidentiality and reporting authority, and it expands/clarifies the Board’s ability to share inspection and disciplinary information with federal health officials and the National Association of Boards of Pharmacy.
Substantively, the bill tightens and details the rules for compounding with bulk drug substances. It requires pharmacists to use bulk substances that meet specified FDA, USP-NF, and quality-control standards, including documentation of certificates of analysis, manufacturing inspections, and impurity testing. It also reinforces limits on compounding “essentially copies” of commercially available drugs, while preserving exceptions for patient-specific changes, shortages, emergent needs, and certain combinations of products. The bill further requires detailed recordkeeping for compounded products, including formula records, lot information, quality assurance plans, and prompt production of records to the Board upon request.
HB917 also addresses office-based administration and veterinary-related compounding. It allows pharmacists to provide compounded products to certain practitioners for administration in their offices under emergency or federal-law conditions, and it sets specific labeling requirements for those products. The bill includes special provisions for companion animals and veterinarians, including limits on distribution for emergent conditions when timely access to a compounding pharmacy is unavailable. In addition, it requires pharmacies and nonresident pharmacies that engage in sterile compounding to notify the Board of their intent to dispense into Virginia.
The bill’s impact on state law is to make Virginia’s compounding framework more explicit and more closely aligned with federal and USP-NF standards, while increasing documentation, traceability, and oversight. It would affect pharmacists, compounding pharmacies, outsourcing facilities, veterinarians, prescribers, and the Board of Pharmacy by imposing more detailed compliance obligations and by expanding the Board’s reporting and inspection-related authority. The bill also exempts the Board’s initial implementing regulations from the Administrative Process Act, though public comment must still be provided.
The general sentiment reflected in the available history is neutral to supportive, but limited by the lack of recorded debate or votes beyond a voice-vote continuation to the next session in the House Health and Human Services Committee. The main points of contention likely center on the bill’s stricter controls over bulk drug substances, the documentation required to justify compounded drugs that are essentially copies of commercial products, and the added compliance burden on pharmacies. At the same time, the bill appears designed to address safety, quality, and oversight concerns in compounding practice, which likely explains its committee consideration.
HB917 would amend §§ 54.1-3406 and 54.1-3410.2 of the Code of Virginia to expand the Board of Pharmacy’s reporting authority, impose more detailed compounding standards, and strengthen recordkeeping and notification requirements for pharmacies and nonresident pharmacies. It would affect compounding pharmacies, pharmacists, prescribers, veterinarians, and the Board by requiring more documentation, quality control, and compliance with USP-NF and FDA-related standards, while also creating clearer limits on copying commercially available drugs and using bulk drug substances.
No committee transcript or recorded vote details are available beyond a voice-vote continuation to the next session in House Health and Human Services. Based on the bill text, the measure appears to be framed as a patient-safety and oversight bill, suggesting generally favorable or at least cautious consideration, with no documented opposition in the provided materials. The absence of debate makes it difficult to identify a strong partisan or stakeholder split from the record provided.
The likely areas of contention are the bill’s tighter restrictions on compounding drugs that are essentially copies of commercially available products, the extensive documentation required to justify exceptions, and the added quality-control and recordkeeping obligations for pharmacies. Pharmacies and compounders may view these provisions as burdensome, while regulators and patient-safety advocates are likely to support them as necessary safeguards. Additional sensitivity may exist around the bill’s treatment of bulk drug substances, emergency compounding, veterinary distribution, and the Board’s expanded information-sharing authority.